NCT02397460View on ClinicalTrials.gov

Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015)

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

April 29, 2015

Primary Completion Date

April 22, 2016

Study Completion Date

May 16, 2016

Conditions
Refractory Chronic Cough
Interventions
DRUG

Gefapixant

Gefapixant tablets administered orally as a single dose of 50 mg (1 tablet) or 300 mg (6 tablets)

DRUG

Placebo

Trial Locations (1)

M23 9QZ

The Medicines Evaluation Unit, Manchester

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02397460 - Effect of Gefapixant (AF-219/MK-7264) on Cough Reflex Sensitivity (MK-7264-015) | Biotech Hunter | Biotech Hunter